ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) Files An 8-K Results of Operations and Financial Condition

ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02. Results of Operations and Financial Condition.

On May 8, 2017, OncoMed Pharmaceuticals, Inc. (the Company)
announced its financial results for the quarter ended March 31,
2017. The full text of the press release issued in connection
with the announcement is furnished as Exhibit 99.1 to this
Current Report on Form 8-K and is located on the Companys website
at www.oncomed.com under For Investors Press Releases.

The information in Item 2.02 of this Current Report on Form 8-K
(including Exhibit 99.1) shall not be deemed filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference under the Securities
Act of 1933, as amended, except as expressly set forth by
specific reference in such a filing, regardless of any general
incorporation language in any such filing, unless the Company
expressly sets forth in such filing that such information is to
be considered filed or incorporated by reference therein.

Item 8.01. Other Events.

On May 8, 2017, in the Press Release, the Company also announced
top-line results from the Companys three arm randomized Phase 2
DENALI clinical trial of demcizumab (anti-DLL4, OMP-21M18) in
combination with carboplatin and pemetrexed in front-line
non-squamous non-small cell lung cancer (NSCLC). The third and
fourth paragraphs of the Press Release are incorporated by
reference herein. The Company further reported in the Press
Release that it has decided to cease dosing patients in the
current vantictumab (anti-Fzd, OMP-18R5) and ipafricept (Fzd8-Fc,
OMP-54F28) Phase 1b studies following a recent bone adverse event
that occurred in a patient receiving vantictumab plus paclitaxel
in the Phase 1b HER2-negative breast cancer trial.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.





Press release dated May 8, 2017 entitled OncoMed
Announces First Quarter 2017 Financial Results and
Demcizumab DENALI Results


OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc. The Company’s Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Ipafricept is the Company’s Wnt pathway modulator. GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein.


ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) closed its last trading session up +0.05 at 3.61 with 357,034 shares trading hands.

An ad to help with our costs